Cargando…

PET-Based Human Dosimetry of (68)Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging

(68)Ga-NODAGA-exendin-4 is a promising tracer for β-cell imaging using PET/CT. Possible applications include preoperative visualization of insulinomas and discrimination between focal and diffuse forms of congenital hyperinsulinism. There is also a significant role for this tracer in extending our k...

Descripción completa

Detalles Bibliográficos
Autores principales: Boss, Marti, Buitinga, Mijke, Jansen, Tom J.P., Brom, Maarten, Visser, Eric P., Gotthardt, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954461/
https://www.ncbi.nlm.nih.gov/pubmed/31519801
http://dx.doi.org/10.2967/jnumed.119.228627
_version_ 1783486799361867776
author Boss, Marti
Buitinga, Mijke
Jansen, Tom J.P.
Brom, Maarten
Visser, Eric P.
Gotthardt, Martin
author_facet Boss, Marti
Buitinga, Mijke
Jansen, Tom J.P.
Brom, Maarten
Visser, Eric P.
Gotthardt, Martin
author_sort Boss, Marti
collection PubMed
description (68)Ga-NODAGA-exendin-4 is a promising tracer for β-cell imaging using PET/CT. Possible applications include preoperative visualization of insulinomas and discrimination between focal and diffuse forms of congenital hyperinsulinism. There is also a significant role for this tracer in extending our knowledge on the role of β-cell mass in the pathophysiology of type 1 and type 2 diabetes by enabling noninvasive quantification of tracer uptake as a measure for β-cell mass. Calculating radiation doses from this tracer is important to assess its safety for use in patients (including young children) with benign diseases and healthy individuals. Methods: Six patients with hyperinsulinemic hypoglycemia were included. After intravenous injection of 100 MBq of the tracer, 4 successive PET/CT scans were obtained at 30, 60, 120, and 240 min after injection. Tracer activity in the pancreas, kidneys, duodenum, and remainder of the body were determined, and time-integrated activity coefficients for the measured organs were calculated. OLINDA/EXM software, version 1.1, was applied to calculate radiation doses using the reference adult male and female models and to estimate radiation doses to children. Results: The mean total effective dose for adults was very low (0.71 ± 0.07 mSv for a standard injected dose of 100 MBq). The organ with the highest absorbed dose was the kidney (47.3 ± 10.2 mGy/100 MBq). The estimated effective dose was 2.32 ± 0.32 mSv for an injected dose of 20 MBq in newborns. This dose decreased to 0.77 ± 0.11 mSv/20 MBq for 1-y-old children and 0.59 ± 0.05 mSv for an injected dose of 30 MBq in 5-y-old children. Conclusion: Our human PET/CT-based dosimetric calculations show that the effective radiation doses from the novel tracer (68)Ga-NODAGA-exendin-4 are very low for adults and children. The doses are lower than reported for other polypeptide tracers such as somatostatin analogs (2.1–2.6 mSv/100 MBq) and are beneficial for application as a research tool, especially when repeated examinations are needed.
format Online
Article
Text
id pubmed-6954461
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Society of Nuclear Medicine
record_format MEDLINE/PubMed
spelling pubmed-69544612020-01-14 PET-Based Human Dosimetry of (68)Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging Boss, Marti Buitinga, Mijke Jansen, Tom J.P. Brom, Maarten Visser, Eric P. Gotthardt, Martin J Nucl Med Radiobiology/Dosimetry (68)Ga-NODAGA-exendin-4 is a promising tracer for β-cell imaging using PET/CT. Possible applications include preoperative visualization of insulinomas and discrimination between focal and diffuse forms of congenital hyperinsulinism. There is also a significant role for this tracer in extending our knowledge on the role of β-cell mass in the pathophysiology of type 1 and type 2 diabetes by enabling noninvasive quantification of tracer uptake as a measure for β-cell mass. Calculating radiation doses from this tracer is important to assess its safety for use in patients (including young children) with benign diseases and healthy individuals. Methods: Six patients with hyperinsulinemic hypoglycemia were included. After intravenous injection of 100 MBq of the tracer, 4 successive PET/CT scans were obtained at 30, 60, 120, and 240 min after injection. Tracer activity in the pancreas, kidneys, duodenum, and remainder of the body were determined, and time-integrated activity coefficients for the measured organs were calculated. OLINDA/EXM software, version 1.1, was applied to calculate radiation doses using the reference adult male and female models and to estimate radiation doses to children. Results: The mean total effective dose for adults was very low (0.71 ± 0.07 mSv for a standard injected dose of 100 MBq). The organ with the highest absorbed dose was the kidney (47.3 ± 10.2 mGy/100 MBq). The estimated effective dose was 2.32 ± 0.32 mSv for an injected dose of 20 MBq in newborns. This dose decreased to 0.77 ± 0.11 mSv/20 MBq for 1-y-old children and 0.59 ± 0.05 mSv for an injected dose of 30 MBq in 5-y-old children. Conclusion: Our human PET/CT-based dosimetric calculations show that the effective radiation doses from the novel tracer (68)Ga-NODAGA-exendin-4 are very low for adults and children. The doses are lower than reported for other polypeptide tracers such as somatostatin analogs (2.1–2.6 mSv/100 MBq) and are beneficial for application as a research tool, especially when repeated examinations are needed. Society of Nuclear Medicine 2020-01 /pmc/articles/PMC6954461/ /pubmed/31519801 http://dx.doi.org/10.2967/jnumed.119.228627 Text en © 2020 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.
spellingShingle Radiobiology/Dosimetry
Boss, Marti
Buitinga, Mijke
Jansen, Tom J.P.
Brom, Maarten
Visser, Eric P.
Gotthardt, Martin
PET-Based Human Dosimetry of (68)Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging
title PET-Based Human Dosimetry of (68)Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging
title_full PET-Based Human Dosimetry of (68)Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging
title_fullStr PET-Based Human Dosimetry of (68)Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging
title_full_unstemmed PET-Based Human Dosimetry of (68)Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging
title_short PET-Based Human Dosimetry of (68)Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging
title_sort pet-based human dosimetry of (68)ga-nodaga-exendin-4, a tracer for β-cell imaging
topic Radiobiology/Dosimetry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954461/
https://www.ncbi.nlm.nih.gov/pubmed/31519801
http://dx.doi.org/10.2967/jnumed.119.228627
work_keys_str_mv AT bossmarti petbasedhumandosimetryof68ganodagaexendin4atracerforbcellimaging
AT buitingamijke petbasedhumandosimetryof68ganodagaexendin4atracerforbcellimaging
AT jansentomjp petbasedhumandosimetryof68ganodagaexendin4atracerforbcellimaging
AT brommaarten petbasedhumandosimetryof68ganodagaexendin4atracerforbcellimaging
AT visserericp petbasedhumandosimetryof68ganodagaexendin4atracerforbcellimaging
AT gotthardtmartin petbasedhumandosimetryof68ganodagaexendin4atracerforbcellimaging